The management of mucous membrane pemphigoid and pemphigus

Richelle M. Knudson, Amer N. Kalaaji, Alison J. Bruce

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


Mucous membrane pemphigoid and pemphigus vulgaris are autoimmune blistering disorders in which many similar drugs and therapeutic strategies are utilized. In general, localized disease can be treated with topical agents. In contrast, patients with more severe and progressive disease usually require a combination of systemic corticosteroids and immunosuppressive medications. Oral corticosteroids, adjuvant immunosuppressive agents, antibiotics such as dapsone and immunomodulatory procedures like intravenous immunoglobulin are the main therapeutic agents used in treating these two disorders. Much of the morbidity and mortality associated with these disorders are related to the sites involved and to the drugs used for therapy. Treatment should be individualized based on severity, extent, and rate of progression of disease, comorbidities, and age of the patient. Serum levels of specific autoantibodies and indirect immunofluorescence titers, in certain cases, can be used to monitor response to therapy.

Original languageEnglish (US)
Pages (from-to)268-280
Number of pages13
JournalDermatologic Therapy
Issue number3
StatePublished - 2010


  • Cicatricial pemphigoid
  • Mucous membrane pemphigoid
  • Pemphigus vulgaris
  • Therapy

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'The management of mucous membrane pemphigoid and pemphigus'. Together they form a unique fingerprint.

Cite this